Article History
Accepted: 4 September 2020
First Online: 8 October 2020
Competing interests
: M.A.D. has been a member of advisory boards for Cancer Therapeutics CRC, Storm Therapeutics, Celgene and Cambridge Epigenetix. S.-J.D. has been a member of the advisory board for AstraZeneca. The S.-J.D. laboratory has received research funding from Genentech. The M.A.D. and S.-J.D. laboratories receive research funding from Cancer Therapeutics CRC. J.-C.M. declares no competing interests.